Skip to content
Italy
-
CVC Capital Partners collaborates with GBL on Recordati’s landmark US$12.4B privatization bid
CVC, already the majority shareholder with a 46.8% stake, has positioned the move as a long-term strategic consolidation rather than a short-term financial transaction.
-
Chiesi strengthens rare disease portfolio with US$1.9B acquisition of KalVista
Under the terms of the agreement, Chiesi will purchase KalVista for US$27 per share, representing a 36% premium over the company’s closing stock price on April 28.
-
CVC Capital Partners targets full acquisition of Recordati in USD12.6B buyout
CVC first invested in Recordati in 2018, paying €3.03 billion (USD 3.5 billion) to acquire a 51.8% controlling stake.
-
CDMO Axplora invests USD60M in Italy to boost high-potential API production
Construction crews have already broken ground on the expansion project, which Axplora expects to complete by February 2027.
-
Alfasigma acquires GSK’s liver disease drug Linerixibat for USD690M deal
Alfasigma will pay GSK USD 300 million upfront, with an additional USD 100 million due upon US Food and Drug Administration (FDA) approval.